阿帕替尼联合替吉奥治疗晚期胃癌患者的效果及对IL-6家族因子的影响

Effect of Apatinib Combined with Tegafur,Gimeracil and Oteracil Potassium in the Treatment of Advanced Gastric Cancer and Its Influence on IL-6 Family Factors

目的:探究阿帕替尼联合替吉奥治疗晚期胃癌患者的效果及对白介素-6(IL-6)家族因子的影响。方法:将2020年4月—2022年11月辽阳市中心医院的90例晚期胃癌患者依据随机数字表法分为对照组45例和观察组45例。对照组采用替吉奥进行治疗,观察组则采用阿帕替尼联合替吉奥进行治疗。比较两组的总有效率、各类不良反应发生率、治疗前后的生存质量[癌症患者生命质量评定30问卷(QLQ-C30)评分]及IL-6家族因子[IL-6、白介素-27(IL-27)及白介素-31(IL-31)]。结果:观察组的总有效率显著高于对照组,差异有统计学意义(P<0.05)。两组的各类不良反应发生率比较,差异均无统计学意义(P>0.05)。治疗前两组的QLQ-C30各维度评分及IL-6家族因子比较,差异均无统计学意义(P>0.05),治疗2个周期及4个周期后观察组的QLQ-C30各维度评分均显著高于对照组,IL-6家族因子均显著低于对照组,差异均有统计学意义(P<0.05)。结论:阿帕替尼联合替吉奥在晚期胃癌患者中的应用效果较好,安全性值得肯定,且可显著改善患者的生存质量及IL-6家族因子的表达,因此在晚期胃癌患者中的应用价值较高。

Objective:To explore the effect of Apatinib combined with Tegafur,Gimeracil and Oteracil Potassiumin in the treatment of advanced gastric cancer patients and the influence on interleukin-6(IL-6)family factors.Method:A total of 90 patients with advanced gastric cancer in Liaoyang Central Hospital from April 2020 to November 2022 were divided into control group(45 cases)and observation group(45 cases)according to random number table method.The control group was treated with Tegafur,Gimeracil and Oteracil Potassium,the observation group was treated with Apatinib combined with Tegafur,Gimeracil and Oteracil Potassium.The total effective rates,various adverse reactions rates,life quality[the quality of life questionnaire core 30(QLQ-C30 score)]and IL-6 family factors[IL-6,interleukin-27(IL-27)and interleukin-31(IL-31)]before and after treatment of two groups were compared.Result:The total effective rate of observation group was significantly higher than that of control group,the difference was statistically significant(P<0.05).The various adverse reactions rates of two groups were compared,the differences were not statistically significant(P>0.05).There were no statistical significance in QLQ-C30 scores and IL-6 family factors between two groups before treatment(P>0.05);after 2 and 4 cycles of treatment,the QLQ-C30 scores of the observation group were significantly higher than those of the control group,and the IL-6 family factors were significantly lower than those of the control group,the differences were statistically significant(P<0.05).Conclusion:The effect of Apatinib combined with Tegafur,Gimeracil and Oteracil Potassium in patients with advanced gastric cancer is better,its safety is confirmed,and it can significantly improve the life quality and expression of IL-6 family factors of patients,so its application value in the patients with advanced gastric cancer is higher.